Home » UL Announces Expanded Testing for Drug Contaminants in Treated Wastewater
UL Announces Expanded Testing for Drug Contaminants in Treated Wastewater
PharmaManufacturing.com
06/22/2010
UL combined its existing methods (L200, L211, L220 & L221) to develop UL test method L222 used for the analysis of Endocrine Disrupting Chemicals (EDCs) and PPCPs. This method focuses on detecting and analyzing nearly 30 most frequently studied and detected contaminants of emerging concern including acetaminophen, bisphenol A, caffeine, DEET, estrone, nicotine, nonylphenol, triclosan, etc. UL also streamlined the analysis of selected semi-volatile organic compounds including sterols, phosphate flame retardants, fragrances, polyaromatic hydrocarbons (PAHs), phenols, and pesticides to create UL method S190. Both the L222 and S190 testing methods are used to analyze contaminants of emerging concern found in treated wastewater, surface water, groundwater and municipal drinking water.
According to a report from IMS Health, a leading provider of market intelligence to the pharmaceutical and healthcare industries, in 2009 global pharmaceutical sales exceeded $773 billion. As a result, the consumption of PPCPs has increased significantly over the last 20 years triggering a rise in the amount of PPCPs entering water supplies through excretion, bathing and the disposal of medications in sewers and trash. Today, UL analytical capabilities include analysis of nearly 120 emerging contaminants including EDCs, PPCPs, flame-retardants, and other contaminants of emerging concern.
“The human health and environmental effects associated with PPCPs in water supplies are not well understood at this time,” said Dennis Leeke, Business Manager, UL Global Water Business. “UL recognizes the importance of this growing issue and is one of only a few laboratories in the country that has developed methods to detect pharmaceuticals and other compounds at ultralow levels. We are committed to supporting the drinking water industry by providing water utilities and government agencies with new ways to detect and analyze emerging contaminants more accurately than ever before.”
As a global leader in drinking water quality and safety, UL has analyzed more than two million drinking water samples for thousands of public and private entities, including the U.S. Environmental Protection Agency. UL tests water representing more than 7,000 municipalities and is certified in 48 states and Puerto Rico. The company also is an approved certifier of water products that meet the criteria of the EPA’s WaterSenseSM program, which identifies and promotes the use of water-efficient products. For more information on UL’s water programs and services, visit the water industry section on www.ul.com.
About Underwriters Laboratories
UL is an independent product safety certification organization that has been testing products and writing Standards for Safety for more than a century. UL evaluates more than 19,000 types of products, components, materials and systems from more than 66,000 manufacturers each year. In total, there are more than 20 billion UL Marks appearing on products worldwide. UL's global family of companies and network of service providers includes 68 laboratory, testing and certification facilities serving customers in 102 countries. For more information, visit: http://www.ul.com/newsroom.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers

Print page